ROHTO PHARMACEUTICAL CO.,LTD. November 11, 2021
Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2022
(Six Months Ended September 30, 2021)
ROHTO Pharmaceutical Co., Ltd. | [Japanese GAAP] | |
Company name: | Stock Exchange listing: TSE, First Section | |
Stock code: | 4527 | URL: https://www.rohto.co.jp/ |
Representative: | Masashi Sugimoto, President and COO | |
Contact: | Masaya Saito, Vice President and Director | |
Telephone: | 81-(0)6-6758-8223 |
Scheduled date of filing of Quarterly Report: | November 12, 2021 |
Scheduled date of dividend payment: | December 2, 2021 |
Supplementary materials for quarterly financial results: | Yes |
Quarterly financial results meeting: | Yes (for institutional investors and analysts) |
(All amounts are rounded down to the nearest million yen.) |
1. Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2022 (April 1, 2021 - September 30, 2021)
(1) Consolidated results of operations | (Percentages represent year-on-year changes.) | |||||||||
Net sales | Operating income | Ordinary income | Profit attributable to | |||||||
owners of parent | ||||||||||
Millions of yen | % | Millions of yen | % | Millions of yen | % | Millions of yen | % | |||
Six months ended Sep. 30, 2022 | 91,019 | - | 13,771 | - | 13,514 | - | 10,756 | - | ||
Six months ended Sep. 30, 2021 | 83,004 | △8.2 | 10,173 | △2.1 | 10,484 | △3.7 | 5,797 | △20.6 |
Note: Comprehensive income (Millions of yen):
Six months ended Sep. 30, 2022: | 13,306 (－%) |
Six months ended Sep. 30, 2021: | 5,384 (13.0%) |
Basic net income | Diluted net income | |
per share | per share | |
Yen | Yen | |
Six months ended Sep. 30, 2022 | 94.30 | 94.03 |
Six months ended Sep. 30, 2021 | 50.83 | 50.68 |
Note 1: Beginning with the first half of the fiscal year ending on March 31, 2022, the Company has applied Accounting Standard for Revenue Recognition (ASBJ Statement No. 29, March 31, 2020). All figures for the first half incorporate this accounting standard and comparisons with the first quarter of the previous fiscal year are omitted.
Note 2: The provisional accounting treatment for business combinations has been finalized at the end of the fiscal year endedMarch 31, 2022. The figures for the first half of the fiscal year ended March 31, 2021 have been restated accordingly.
(2) Consolidated financial position
Total assets | Net assets | Equity ratio | |||
As of Sep. 30, 2022 | Millions of yen | Millions of yen | % | ||
261,458 | 172,567 | 63.5 | |||
As of Mar. 31, 2021 | 225,790 | 156,612 | 68.9 | ||
Reference: Shareholders' equity (Millions of yen): | As of Sep. 30, 2022: 166,101 | As of Mar. 31, 2021: 155,525 |
2. Dividends
Dividend per share | ||||||||||
1Q-end | 2Q-end | 3Q-end | Year-end | Total | ||||||
Yen | Yen | Yen | Yen | Yen | ||||||
Fiscal year ended Mar. 31, 2021 | - | 13.00 | - | 15.00 | 28.00 | |||||
Fiscal year ending Mar. 31, 2022 | - | 15.00 | ||||||||
Fiscal year ending Mar. 31, 2022 | - | 15.00 | 30.00 | |||||||
(forecast) | ||||||||||
Note: Revisions to the most recently announced dividend forecast: None |
3. Consolidated Earnings Forecast for the Fiscal Year Ending March 31, 2022 (April 1, 2021 - March 31, 2022)
(Percentages represent year-on-year changes.)
Net sales | Operating income | Ordinary income | Profit attributable to | Net income per share | ||||||
owners of parent | ||||||||||
Millions of yen | % | Millions of yen | % | Millions of yen | % | Millions of yen | % | Yen | ||
Full year | 190,000 | (4.8) | 25,000 | (8.7) | 25,000 | (4.6) | 18,000 | (7.5) | 157.80 |
Note: Revisions to the most recently announced consolidated forecast: Yes
* Notes
- Changes in significant subsidiaries during the period (changes in specific subsidiaries resulting in change in scope of consolidation): None
- Application of special accounting methods for preparation of quarterly consolidated financial statements: Yes
Note: Please refer to page 11 of the attachments "2. Quarterly Consolidated Financial Statements and Major Notes, (4) Notes to Quarterly Consolidated Financial Statements" for further information.
- Changes in accounting policies and accounting estimates, and restatements
- Changes in accounting policies due to revisions in accounting standards: None
- Changes in accounting policies other than 1) above: None
- Changes in accounting estimates: None
- Restatements: None
Note: Please refer to page 11 of the attachments "2. Quarterly Consolidated Financial Statements and Major Notes, (4) Notes to Quarterly Consolidated Financial Statements" for further information.
- Number of common shares issued
- Number of shares outstanding at the end of the period (including treasury shares):
As of Sep. 30, 2022: | 118,089,155 shares | As of Mar. 31, 2021: | 118,089,155 shares |
2) Number of shares of treasury shares at the end of the period:
As of Sep. 30, 2022: | 4,019,085 shares | As of Mar. 31, 2020: | 4,019,044 shares |
3) Average number of shares outstanding during the period:
Six months ended Sep. 30, 2022: | 114,070,103 shares | Six months ended Sep. 30, 2021: | 114,070,160 shares |
Note 1: This summary report is not subject to the quarterly review conducted by certified public accountants or audit firms.
Note 2: Cautionary statement with respect to forward-looking statements and other special items
Forecasts regarding future performance in these materials are based on assumptions judged to be valid and information available to the Company at the time the materials were created. These materials are not promises by the Company regarding future performance. Actual results of operations may differ significantly from the forecasts depending on various factors. For discussion of the assumptions and other factors considered by the Company in preparing the above projections, please refer to page 4 of the attachments "1. Qualitative Information on Quarterly Consolidated Financial Performance, (3) Explanation of Consolidated Earnings Forecast and Other Forward-looking Statements."
ROHTO Pharmaceutical Co., Ltd. (4527) Financial Results for the Second Quarter of FY3/22
Contents of Attachments | ||
1. Qualitative Information on Quarterly Consolidated Financial Performance | 2 | |
(1) | Explanation of Results of Operations | 2 |
(2) | Explanation of Financial Position | 3 |
(3) | Explanation of Consolidated Earnings Forecast and Other Forward-looking Statements | 4 |
2. Quarterly Consolidated Financial Statements and Major Notes | 5 | |
(1) | Quarterly Consolidated Balance Sheets | 5 |
(2) | Quarterly Consolidated Statements of Income and Comprehensive Income | 7 |
(3) | Quarterly Consolidated Statements of Cash Flows | 9 |
(4) | Notes to Quarterly Consolidated Financial Statements | 11 |
Going Concern Assumption | 11 | |
Significant Changes in Shareholders' Equity | 11 | |
Application of Special Accounting Methods for Preparation of Quarterly Consolidated Financial Statements | 12 | |
Segment Information | 13 |
1
ROHTO Pharmaceutical Co., Ltd. (4527) Financial Results for the Second Quarter of FY3/22
1. Qualitative Information on Quarterly Consolidated Financial Performance
(1) Explanation of Results of Operations
In the first half of the current fiscal year, the severe economic situation continued due to the impact of COVID-19. However, the numbers of infected and seriously ill people fell as the vaccination rate rose, and at the end of September the government decided to lift the state of emergency. While the future remains uncertain, the economy is expected to recover.
Under these circumstances, the Rohto Group has created the slogan of "Connect for Well-being," suggesting people around the world living energetically and happily each day, both physically and mentally, throughout the various stages of their lives. We are endeavoring to further increase corporate value. To this end, we are working toward the realization of the "Management Vision 2030".
In total, net sales rose sharply to 91,019 million yen. The impact of COVID-19 caused a sharp fall in sales in the same period of the previous year, but in the current period, despite the spread of new variants, there was a substantial increase in vaccination rate which enabled economic activities to restart. Consumer sentiment also showed the sign of recovery, resulting in a significant boost to sales.
Regarding profits, there was a sharp increase at all levels. Due to the significant increase in sales and efficient use of selling, general and administrative expenses, operating income, ordinary income and profit attributable to owners of parent increased to 13,771 million yen, 13,514 million yen and 10,756 million yen, respectively.
Note: Beginning with the first quarter of the fiscal year ending on March 31, 2022, the Company has applied the Accounting Standard for Revenue Recognition (ASBJ Statement No. 29). As a result, the accounting treatment for revenue differs from the first half of the previous fiscal year. The rate of change from the prior first half was not given in the narrative. If we were to apply the new revenue recognition standard to the prior first half, the rate of change was as follows: sales rose 15.5%, operating income 36.7%, ordinary income 30.2%, and profit attributable to owners of parent 88.9% year-on-year. Sales and profits at all levels increased to all-time highs.
Results by reportable segment are as follows.
Japan
Sales to customers were 56,901 million yen.
Although the state of emergency was declared, sales of sunscreens, contact lens and contact lens care solution increased, and "Melano CC," "Deoco" and "Rohto V5 Grain" continued to perform well. Moreover, the OEM rapid test kit for the COVID-19 antigen aided sales growth.
In addition, Qualitech Pharma Co., Ltd. and Nitten Pharmaceutical Co., Ltd. also contributed to the increase in sales. Segment profit (operating income) amounted to 9,359 million yen as a significant rise in sales absorbed the increase in selling, general, and administrative expenses.
Note: As described in the note for "(1) Explanation of Results of Operations," if we were to apply the new revenue recognition standard to the prior first half, sales rose 11.3% and operating income 32.0% year-on-year.
America
Sales to customers increased 6.3% year-on-year to 4,026 million yen.
With the numbers of the COVID-19 infected declining, people started to go out more often. As a result, sales of eye drops and "OXY," an acne treatment, progressed strongly.
Despite higher procurement costs for raw materials and supplies, segment profit (operating income) turned profitable at 147 million yen (compared with 88 million yen loss in prior first half) due to efficient use of selling, general and
2
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Rohto Pharmaceutical Co. Ltd. published this content on 18 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 November 2021 08:31:08 UTC.
